18 years ago Brazil welcomed the country’s first generic drug registration. According to the National Agency for Sanitary Vigilance Agency (Anvisa), prescription of generic drugs increased 65% from 2015 to 2018. Between February of last year and February of this year, 34% of the 115 million medical prescriptions issued were generic versions.
The implementation of the policy of generic medicines in Brazil began in 1999 and is considered to have been quite effective, both because it increased the access of the population to drugs, and also from the point of view of the creation of a more robust national pharmaceutical industry.
Before the measure came into force, only one of the top ten pharmaceutical companies in the country was a national. Currently the number reaches five. The catalogue of generic drugs available in Brazil consists of 6,300 products, manufactured by 120 laboratories. Last year, 70% of all pharmacological units produced in the country were generic. In addition, from 2014 to 2017 the number of new generic drugs grew by 130.1%.
Despite the obvious success and widespread approval by consumers, there is still rejection of generic drugs by many health professionals. The lack of knowledge about scientific evidence and the criterion of validation of generics in medical schools is pointed out as one of the possible reasons for rejection.
Is there still prejudice on the part of healthcare professionals in the prescription of generic drugs? You can find below what the M3 Global Research community answered to this question.
Let us hear your opinion on this by signing up to receive the Monthly Pulse via email and to take part in paid medical studies.